Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies

A S Abutaily, B J Addis, W R Roche

ORIGINAL ARTICLE

T he diagnosis of malignant mesothelioma is dependent on an assessment of clinical and radiological findings in conjunction with pleural fluid cytology and pleural biopsy. Even when thoracoscopy is used to obtain sufficient tissue, the histological diagnosis may prove elusive for several reasons. These include distinguishing well differentiated epithelioid mesothelioma from reactive mesothelial proliferation, sarcomatoid or desmoplastic mesothelioma from reactive pleural fibrosis, and epithelioid mesothelioma from metastatic or pseudomesotheliomatous carcinoma, usually adenocarcinoma. Immunohistochemistry has proved most useful in the last of these situations but, despite many antibodies showing potential, it is generally agreed that no one antibody shows absolute specificity or sensitivity for either tumour. Therefore, laboratories dealing with mesothelioma cases on a regular basis have developed panels of antibodies, whereby the probability of a tumour being a mesothelioma can be assessed. To refine this process further, we have used a group of newer antibodies in addition to our standard panel of antibodies to calretinin, E-cadherin, N-cadherin, surfactant apoprotein A (SP-A), thyroid transcription factor 1 (TTF-1), thrombomodulin, and cytokeratin 5/6, and applied in the streptavidin–biotin–peroxidase complex procedure on formalin fixed, paraffin wax embedded tissue.

Aim: The value of immunohistochemical staining in differentiating between malignant mesothelioma and pulmonary adenocarcinoma was re-examined using newly available commercial antibodies, with the aim of increasing the sensitivity and specificity of diagnosis, and simplifying the antibody panel required.

Methods: Forty-one malignant mesotheliomas and 35 lung adenocarcinomas were studied. Commercial antibodies to calretinin, E-cadherin, N-cadherin, surfactant apoprotein A (SP-A), thyroid transcription factor 1 (TTF-1), thrombomodulin, and cytokeratin 5/6 were applied using the streptavidin–biotin–peroxidase complex procedure on formalin fixed, paraffin wax embedded tissue.

Results: E-cadherin was expressed in all adenocarcinomas and in 22% of the mesotheliomas. TTF-1 expression was detected in 69% of the adenocarcinomas and none of the mesotheliomas. Positive staining with polyclonal anti-calretinin was detected in 80% of the mesotheliomas and 6% of the adenocarcinomas. N-cadherin was expressed in 78% of mesotheliomas and 26% of adenocarcinomas. Thrombomodulin was expressed in 6% of the adenocarcinomas and in 53% of the mesotheliomas. Cytokeratin 5/6 expression was detected in 6% of the adenocarcinomas and 63% of the mesotheliomas. The results were compared with the standard laboratory panel for mesothelioma diagnosis: anti-carinoembryonic antigen (anti-CEA), LeuM1, BerEP4, and HBME-1. The application of these two antibodies alone was adequate for the diagnosis of 69% of adenocarcinomas and 78% of mesotheliomas. Where TTF-1 is negative and E-cadherin is positive, a secondary panel of antibodies, including BerEP4 and LeuM1 (CD15) and antibodies directed against CEA, calretinin, cytokeratin 5/6, thrombomodulin, and N-cadherin, is required for differentiation between malignant mesothelioma and pulmonary adenocarcinoma.

Immunohistochemical staining procedure

Immunohistochemical studies were performed on formalin fixed, paraffin wax embedded tissue sections using the streptavidin–biotin–peroxidase complex method. Sections were cut at 4 μm thickness and mounted on APES coated slides, dewaxed in xylene, and rehydrated in graded ethanol. The sections were treated with freshly prepared 30% hydrogen peroxide in absolute methanol for 10 minutes to inhibit endogenous peroxidase activity and washed in Tris buffered saline (TBS). Where antigen retrieval was required, the sections were pretreated with either 0.05% pronase (Dako, Ely, UK) in TBS at room temperature for 15 to 20 minutes or sections were immersed in 0.01M citrate buffer and heated by microwave or on a hot plate for 20 to 25 minutes.

Material and Methods

Tumour specimens

The material included in our study was obtained from the archives of the department of cellular pathology at the Southampton General Hospital. The 76 cases included 41 open or thoracoscopic biopsies of malignant mesothelioma (11 epithelioid, seven sarcomatoid, and 23 mixed) and 35 sequential cases of resected primary pulmonary adenocarcinomas. The mesothelioma cases were from 1990 to 1997, whereas the adenocarcinomas were from the years 1997 and 1998. All biopsy specimens were fixed in 10% neutral buffered formalin and routinely processed to paraffin wax.

Abbreviations: CEA, carcinoembryonic antigen; SPA, surfactant apoprotein A; TBS, Tris buffered saline; TTF-1, thyroid transcription factor 1
following by washing in TBS. To minimise non-specific background staining, sections were preincubated with normal swine serum for 20 minutes and then incubated with the primary antibodies (table 1), either for 60 minutes at room temperature or for 18 to 24 hours overnight at 4° C in a moist chamber. The secondary antibody was a 1/200 dilution of either biotinylated sheep antimouse immunoglobulin for monoclonal antibodies or biotinylated swine antirabbit immunoglobulin for polyclonal antibodies (Amersham Pharmacia Biotech, Little Chalfont, UK) for 30 minutes at room temperature. After a further rinse in TBS, the sections were incubated with streptavidin–biotin–peroxidase complexes (1/200 dilution; Dako) for 30 minutes at room temperature, followed by washing in TBS. The colour was developed with the use of 3′,3′-diaminobenzidine substrate solution (DAB).

Sections were then washed, counterstained with Harris’s haematoxylin, dehydrated, cleared in xylene, and mounted with DPX.

RESULTS

Adenocarcinoma

Table 2 summarises the results from the 35 cases of pulmonary adenocarcinoma. All 35 cases of adenocarcinoma were positive for E-cadherin and surfactant apoprotein A (SP-A). Immunoreactivity for E-cadherin was confined to the cell membranes of the tumour cells (fig 1A), whereas SP-A immunoreactivity appeared to be either cytoplasmic (74%) or on the cell membranes (26%). Twenty four of the 34 (69%) adenocarcinoma cases expressed thyroid transcription factor 1.
transcription factor 1 (TTF-1), which was clearly located in the cell nuclei (fig 2A). The percentage positivity was similar for poorly differentiated adenocarcinomas with a solid cell pattern. Nine cases (26%) of pulmonary adenocarcinoma expressed N-cadherin, which was present mainly in the cytoplasm and less frequently on the cell membrane (fig 3A). Only two cases (6%) of adenocarcinoma showed labelling for calretinin in a cytoplasmic and nuclear pattern (fig 4A). Only two of the 35 adenocarcinomas (6%), one of which was a poorly differentiated tumour with a solid pattern, stained for thrombomodulin, expression being localised in the cell membrane. Two cases (6%) of adenocarcinoma showed staining for cytokeratin 5/6, and localisation was both pericellular at the cell membrane and cytoplasmic.
Malignant mesothelioma

Tables 2 and 3 show the results of the immunohistochemical staining with the newly available antibodies in the 41 cases of mesothelioma. None of the malignant mesotheliomas showed immunoreactivity for TTF-1 or LeuM1, 2% were positive for CEA, 7% showed positivity for BerEP4, and 22% were cell membrane positive for E-cadherin (fig 1B). Of the positive markers for mesothelioma, calretinin was present in 80% of cases (fig 4B), N-cadherin was expressed in 78% of cases, and HBME-1 in 63% of cases. SP-A immunoreactivity was detected in 98% of mesotheliomas. Thrombomodulin was expressed at the cell membrane in 53% of the mesotheliomas (fig 5B). Sixty three percent of mesotheliomas showed positive staining for cytokeratin 5/6, in 72% of these staining was pericellular and cytoplasmic, whereas 24% showed cytoplasmic staining only (fig 6B).

Subtypes of mesothelioma

The distribution of immunoreactivity was not uniform in the subtypes of malignant mesothelioma (table 4): calretinin and E-cadherin were expressed mainly by epithelioid and mixed mesotheliomas and N-cadherin was highly expressed in all subtypes of mesothelioma. Thrombomodulin and cytokeratin 5/6 reactivity was also highest in epithelioid mesotheliomas.

Sensitivity and specificity

We examined the results for both the conventional laboratory panel and the new antibodies to investigate the ability of these antibodies to discriminate between mesothelioma and pulmonary adenocarcinoma. TTF-1 was 100% specific for pulmonary adenocarcinoma and detected 69% of cases. E-cadherin was 100% sensitive for adenocarcinoma but was less specific, staining 22% of mesotheliomas. The combination of these two antibodies allowed the detection of pulmonary adenocarcinoma (TTF-1 and E-cadherin positive) with 100% specificity in 69% of cases and excluded pulmonary adenocarcinoma (TTF-1 and E-cadherin negative) with 100% specificity in 78%

### Table 3
Comparison of conventional antibodies with new antibodies in mesothelioma

<table>
<thead>
<tr>
<th>Antibody/antigen</th>
<th>Positive (%)</th>
<th>Negative (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CEA</td>
<td>2</td>
<td>98</td>
</tr>
<tr>
<td>BerEP4</td>
<td>7</td>
<td>93</td>
</tr>
<tr>
<td>HBME-1</td>
<td>63</td>
<td>37</td>
</tr>
<tr>
<td>LeuM1 (CD15)</td>
<td>0</td>
<td>100</td>
</tr>
<tr>
<td>Calretinin</td>
<td>80</td>
<td>20</td>
</tr>
<tr>
<td>Cytokeratin 5/6</td>
<td>63</td>
<td>37</td>
</tr>
<tr>
<td>E-cadherin</td>
<td>22</td>
<td>78</td>
</tr>
<tr>
<td>N-cadherin</td>
<td>78</td>
<td>22</td>
</tr>
<tr>
<td>SPA</td>
<td>98</td>
<td>2</td>
</tr>
<tr>
<td>Thrombomodulin</td>
<td>53</td>
<td>47</td>
</tr>
<tr>
<td>TTF-1</td>
<td>0</td>
<td>100</td>
</tr>
</tbody>
</table>

CEA, carcinoembryonic antigen; SPA-1, surfactant apoprotein A; TTF-1, thyroid transcription factor 1.

Figure 5 Immunostaining for thrombomodulin in (A) adenocarcinoma and (B) mesothelioma. The staining is localised to the cell membrane in mesothelioma and is negative in adenocarcinoma, with positive endothelial staining.

Figure 6 Immunostaining for cytokeratin 5/6 in (A) adenocarcinoma and (B) mesothelioma. Staining was negative in adenocarcinoma and both pericellular and cytoplasmic in mesothelioma.
of mesotheliomas. There were no TTF-1 positive, E-cadherin negative tumours.

The remaining cases of E-cadherin-positive, TTF-1 negative tumours required the application of the other antibodies. Each case was examined to determine the value of the individual antibodies and to determine any overlapping immunoreactivity. CEA was specific for the residual adenocarcinomas, with positivity in nine of 11 cases and no reactivity with the nine E-cadherin positive mesotheliomas. BerEP4 stained 10 of 11 TTF-1 negative adenocarcinomas, but was also positive in two of the nine mesotheliomas. LeuM1 (CD15) was negative in all the mesotheliomas and stained five of the 11 adenocarcinomas. All of the CD15 positive adenocarcinomas were also positive for BerEP4, but the BerEP4 positive mesotheliomas were CD15 negative. Calretinin was positive in one of the 11 adenocarcinomas but this case was CEA positive. Calretinin was positive in all nine E-cadherin positive mesotheliomas. N-cadherin was negative in all 11 adenocarcinomas and positive in seven of nine mesotheliomas. Thrombomodulin was negative in all 11 adenocarcinomas and was positive in six of nine mesotheliomas. Cytokeratin 5/6 was positive in one of the 11 adenocarcinomas and positive in seven of the nine mesotheliomas. HBME1 had little discriminatory value, being positive in six of 11 adenocarcinomas and positive in all the mesotheliomas.

**DISCUSSION**

Some pulmonary adenocarcinomas and many metastatic adenocarcinomas produce epithelial mucin and the simplest and most reliable way to identify these is by means of periodic acid Schiff staining after diastase digestion, although incomplete glycolgen digestion or, rarely, true positivity may occur focally in epithelioid mesotheliomas. For the remainder of the cases, a wide variety of antibodies has been used to make the distinction from malignant mesothelioma, and the use of a panel of antibodies is now accepted practice. The choice of antibodies varies and it is recognised that those chosen for our study are not comprehensive. Among those not included but of potential value are antibodies to cytokeratin 7 and specific antibodies raised against mesothelial cells.

The antibody HBME-1 is widely used but its value depends on reported differences in staining patterns between mesothelioma and carcinoma, rather than the specificity of immunoreactivity. In our experience, these appearances are not easy to interpret in an individual case. Experience with the other antibodies in our established panel, monoclonal anti-CEA, LeuM1, and BerEP4, are well documented and their usefulness depends on their general lack of reactivity with mesothelioma cells. Our current study supports the findings of previous series and shows that no single antibody is entirely satisfactory in this regard. Although it seems that LeuM1 may be most specific because it did not stain mesotheliomas, it also failed to stain six of the 11 adenocarcinomas and is therefore less sensitive than the other antibodies. BerEP4 is the most sensitive of the three but at the same time is the least specific.

"Although E-cadherin shows some lack of specificity, use can be made of the fact that no example of adenocarcinoma in our series failed to stain with this antibody, the inference being that if staining is negative the tumour cannot be an adenocarcinoma"

The antibody to SP-A was disappointing in its ability to discriminate between the two types of tumour and lacked sufficient specificity to justify inclusion in a panel designed for this purpose. Regardless of slight differences in the pattern of staining for SP-A in mesothelioma, this antibody reacts with most types of tumour. Comparable findings are reported in other series. Although E-cadherin shows some lack of specificity, use can be made of the fact that no example of adenocarcinoma in our series failed to stain with this antibody, the inference being that if staining is negative the tumour cannot be an adenocarcinoma. N-cadherin is less specific but its staining of sarcomatoid mesotheliomas may be useful.

TTF-1 is a 38 kDa nuclear protein that was originally identified in thyroid epithelial cells, where it acts as a mediator of thyroid specific gene transcription and activation of thyroglobulin and thyroperoxidase. It is also present in the developing fetal lung, where it is localised to the nuclei of developing airways. In the mature lung, it is selectively expressed by type II alveolar epithelial cells and a subset of bronchiolar epithelial cells, and may act as a factor for the transcription of surfactant apoproteins. It is not expressed in mesoderm derived cells and this may account for its absence from mesothelial cells. Previous studies have shown that TTF-1 expression is retained in thyroid carcinomas and in up to 75% of pulmonary adenocarcinomas. It is not expressed in adenocarcinomas from other sites, and our results support the findings of other authors that malignant mesotheliomas are also invariably negative.

Anticalretinin is one of the few antibodies that is more frequently reactive in mesotheliomas than in adenocarcinomas. Like anti-CEA, care must be taken to exclude positive staining of inflammatory cells because reactivity was seen in tumour associated macrophages. However, we found it to be useful in discriminating E-cadherin positive epithelioid mesotheliomas from pulmonary adenocarcinomas. Thrombomodulin is a protein cofactor expressed on endothelial cell surfaces that modifies the substrate specificity of thrombin, activating the protein C anticoagulant pathway. Thrombomodulin has been shown to be more reactive in mesotheliomas than adenocarcinomas. In our study, we found that thrombomodulin was expressed in 53% of the mesotheliomas, but the staining pattern tended to be focal. The remaining 47% may have included false negatives as a result of the focal expression of thrombomodulin. The sensitivity of this marker might be improved by staining of multiple blocks from large tumour specimens, but this is not feasible with small biopsies.

The antibody to SP-A was disappointing in its ability to discriminate between the two types of tumour and lacked sufficient specificity to justify inclusion in a panel designed for this purpose. Regardless of slight differences in the pattern of staining for SP-A in mesothelioma, this antibody reacts with most types of tumour. Comparable findings are reported in other series. Although E-cadherin shows some lack of specificity, use can be made of the fact that no example of adenocarcinoma in our series failed to stain with this antibody, the inference being that if staining is negative the tumour cannot be an adenocarcinoma."
Our results suggest that the first line antibodies should be E-cadherin and TTF-1 (fig 7). Tumours that show reactivity for both of these antibodies are unequivocally not mesotheliomas and, in the case of primary tumours, are pulmonary adenocarcinomas. Individually, both antibodies have deficiencies; anti-E-cadherin is not specific and anti-TTF-1 has limited sensitivity. Nevertheless, 69% of the adenocarcinomas in our series could be confidently classified at this stage, irrespective of the degree of differentiation. Tumours that lack reactivity for both antibodies are not adenocarcinomas and this accounts for 78% of mesotheliomas.

No tumours were TTF-1 positive and E-cadherin negative. However, those tumours staining for E-cadherin but not for TTF-1 will include 31% of adenocarcinomas and 22% of mesotheliomas. Within this group, most tumours reacting with calretinin will be mesotheliomas. At this stage, however, a very small number of adenocarcinomas will also react and there is therefore an element of uncertainty. The use of the standard panel of antibodies (anti-CEA, CD15, and BerEP4) with the inclusion of antibodies to calretinin, N-cadherin, thrombomodulin, and cytokeratin 5/6 should enable most of these cases to be classified. This approach reduces the panel of antibodies required for most cases and allows for reporting with a greater degree of certainty as to whether a pleural tumour represents malignant mesothelioma or pulmonary adenocarcinoma.

**Take home messages**

- E-cadherin was expressed in all adenocarcinomas and in 22% of the mesotheliomas, whereas thyroid transcription factor 1 (TTF-1) was expressed in 69% of the adenocarcinomas and none of the mesotheliomas.
- Thus, E-cadherin was 100% sensitive for pulmonary adenocarcinoma and TTF-1 was 100% specific for pulmonary adenocarcinoma.
- The combination of these two antibodies alone was adequate for the diagnosis of 69% of adenocarcinomas and 78% of mesotheliomas.
- Tumours that show reactivity for both of these antibodies are unequivocally not mesotheliomas and, in the case of primary tumours, are pulmonary adenocarcinomas.
- Where TTF-1 is negative and E-cadherin is positive, a secondary panel of antibodies, including BerEP4 and LeuM1 (CD15) and antibodies directed against carcinomaembryonic antigen, calretinin, cytokeratin 5/6, thrombomodulin, and N-cadherin, is required for differentiation between malignant mesothelioma and pulmonary adenocarcinoma.
- This approach reduces the panel of antibodies required for most cases and improves the degree of certainty as to whether a pleural tumour represents malignant mesothelioma or pulmonary adenocarcinoma.

**Authors’ affiliations**

A S Abutaily, W R Roche, Respiratory Cell and Molecular Biology, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, UK

B J Addis, Department of Cellular Pathology, Southampton University Hospitals NHS Trust, Southampton SO16 6YD, UK
mesothelioma from pulmonary adenocarcinoma.

N-cadherin and E-cadherin distinguishes pleural mesothelioma from lung adenocarcinoma of the lung and malignant mesothelioma: predictive value and reproductivity of immunoreactive antibodies.


Applications are invited for the post of:

Editor


Clinically orientated pathologists as well as non-medically qualified clinical scientists are invited to apply for the post of Editor. Please send a letter of application, curriculum vitae, a short statement about the strengths and weaknesses of the journal and its edition, and your proposed editorial policy.

Full editorial support will be provided and it is envisaged that the editor will need to devote the equivalent of 1 day per week to the journal. The editorial office is based at BMA House in London.

Journal of Clinical Pathology is an international journal and we seek applicants world wide. Joint applications from two or more candidates wishing to act as co-Editors will be considered.

Closing date is 30 October 2002. Interviews will be held on 13 November 2002 in the afternoon to enable the successful candidate(s) to take up the post in January 2003.

Details of the post can be discussed with the current editor (Helen Holzel, email: helenholzel@compuserve.com) or Mrs Alex Williamson, to whom applications should be sent. A job description and further details about the journal are available on request.

Mrs Alex Williamson, BMJ Publishing Group, BMA House, Tavistock Square, London WC1H 9JR, UK. Telephone: +44 (0)20 7383 6169; Fax: +44 (0)20 7383 6668; email: awilliamson@bmjgroup.com

www.jclinpath.com
Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies
A S Abutaily, B J Addis and W R Roche

doi: 10.1136/jcp.55.9.662

Updated information and services can be found at:
http://jcp.bmj.com/content/55/9/662

These include:

References
This article cites 36 articles, 6 of which you can access for free at:
http://jcp.bmj.com/content/55/9/662#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
- Respiratory cancer (33)
- Lung cancer (oncology) (120)
- Lung cancer (respiratory medicine) (120)
- Immunology (including allergy) (1664)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/